| Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. PS Gill, BM Espina, F Muggia, S Cabriales, A Tulpule, JA Esplin, ... Journal of clinical Oncology 13 (4), 996-1003, 1995 | 324 | 1995 |
| Ligand-targeted liposomes E Forssen, M Willis Advanced drug delivery reviews 29 (3), 249-271, 1998 | 277 | 1998 |
| Selective in Vivo Localization of Daunorubicin Small Unilamellar Vesicles in Solid Tumors EA Forssen, DM Coulter, RT Proffitt Cancer Research 52 (12), 3255-3261, 1992 | 257 | 1992 |
| Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. EA Forssen, ZA Tökès Proceedings of the National Academy of Sciences 78 (3), 1873-1877, 1981 | 255 | 1981 |
| Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes EA Forssen, ZA Tökes Cancer research 43 (2), 546-550, 1983 | 163 | 1983 |
| Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue EA Forssen, R Male-Brune, JP Adler-Moore, MJA Lee, PG Schmidt, ... Cancer Research 56 (9), 2066-2075, 1996 | 151 | 1996 |
| Daunoxome® treatment of solid tumors: preclinical and clinical investigations EA Forssen, ME Ross Journal of liposome research 4 (1), 481-512, 1994 | 146 | 1994 |
| Ligand-targeted liposomes. M Willis, E Forssen Advanced Drug Delivery Reviews 29 (3), 249-271, 1998 | 144 | 1998 |
| The design and development of DaunoXome® for solid tumor targeting in vivo EA Forssen Advanced drug delivery reviews 24 (2-3), 133-150, 1997 | 143 | 1997 |
| Invitro and invivo studies with adriamycin liposomes EA Forssen, ZA Tőkés Biochemical and biophysical research communications 91 (4), 1295-1301, 1979 | 115 | 1979 |
| Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes EA Forssen US Patent 4,946,683, 1990 | 96 | 1990 |
| Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. EA Forssen, ZA Tökes Cancer treatment reports 67 (5), 481-484, 1983 | 68 | 1983 |
| Antracycline antineoplastic agents encapsulated in phospholipid vesicle particles and methods for using same for tumor therapy EA Forssen US Patent 4,769,250, 1988 | 64 | 1988 |
| Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties E Forssen, G Cox, D Hair US Patent 6,120,800, 2000 | 26 | 2000 |
| Chemotherapy with anthracycline liposomes EA Forssen Liposomes as drug carriers: recent trends and progress, Gregoriadis, G.(ed …, 1988 | 22 | 1988 |
| Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties E Forssen, G Cox, D Hair US Patent 5,714,163, 1998 | 21 | 1998 |
| Liposomal vincristine for the treatment of human acute lymphoblastic leukaemia in severe combined immunodeficient (SCID) mice. JL Millar, BC Millar, RL Powles, JPC Steele, RD Clutterbuck, PLR Mitchell, ... British journal of haematology 102 (3), 1998 | 19 | 1998 |
| Phospholipid prodrug inhibitors of the HIV protease: Antiviral activity and pharmacokinetics in rats KY Hostetler, DD Richman, EA Forssen, L Selk, R Basava, MF Gardner, ... Biochemical pharmacology 48 (7), 1399-1404, 1994 | 17 | 1994 |
| Formulations of biologics for intravesical instillation EA Forssen, PM Hughes, DC Rupp, T Hunt, G Shimizu, J Francis, ... US Patent 9,943,576, 2018 | 13 | 2018 |
| DaunoXome®(Liposomal Daunorubicin) for first-line treatment of advanced, HIV-related Kaposi’s Sarcoma G Mukwaya, EA Forssen, P Schmidt, M Ross Long Circulating Liposomes: Old Drugs, New Therapeutics, 147-163, 1998 | 10 | 1998 |
